Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Leslie Popplewell
Phase I/Ii Multicenter Clinical Trial of Lenalidomide Maintenance After Allogeneic Hematopoietic Cell Transplant (alloHCT) in Patients With High Risk (HR) Multiple Myeloma (MM)
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Related publications
CD34-selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed, High-Risk Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Extramedullary vs Medullary Relapse After Autologous or Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Multiple Myeloma (MM) and Its Correlation to Clinical Outcome
Bone Marrow Transplantation
Transplantation
Hematology
Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With Fludarabine/Melphalan in Patients With Myelofibrosis
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Acute Cognitive Impairment in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant
Cancer
Cancer Research
Oncology
Post-Transplant Lymphoproliferative Disorder in Patients With Lymphoma After Allogeneic Hematopoietic Stem Cell Transplantation
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Lenalidomide Induced Graft-Versus-Host Disease in a Patient With Relapsed Multiple Myeloma Three and a Half Years After Allogeneic Hematopoietic Stem Cell Transplantation
Journal of Hematopoietic Cell Transplantation
Phase II Trial to Investigate Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib
British Journal of Haematology
Hematology
